How does "pattern care" differ from "step therapy"? Does the bionic pancreas work? Why is incretin therapy taking off? Here, a 5-slide review of these and other hot topics from the 2014 ADA Scientific Sessions.
Posters at ADA 2014 showcased growing popularity of the incretin therapies and SGLT2 inhibitors. Most fascinating to this diabetologist blogger was use of insulin and a GLP-1 RA in a fixed-combination product.
The latest version of this wearable, automated device can improve glycemia without increasing hypoglycemia. It can handle a wide range of dosing requirements.
Insulin resistance in obese persons at risk for diabetes may be improved with resveratrol used as a dietary supplement, but don’t expect health benefits from resveratrol in red wine.
A genetic variant involved in regulating food intake may play a role in how body mass index affects patients’ susceptibility to diabetes. Reducing total energy intake might help prevent obesity.
The endocrinologist, the primary care physician, the nurse practitioner: who will do what in the coming days of diabetes care? Just one of the debates going on at the ADA conference.
Here's why incretins are catching on . . . and a strategy that treats not just the whole patient but the whole problem. Live from the ADA convention, highlights here.
Correcting Vitamin D deficiency in susceptible diabetes patients could have considerable metabolic benefit.